Abstract
Hospital information system (HIS) data from 18 hospitals was analyzed. 107 723 cases were divided into two groups, those that received Shuxuetong and those that did not. Patients, 18 to 80 years old, suffering from cerebral infarction, whose treatment outcome was clear were selected. Resulting in 7 520 cases in the treatment group and 3 353 who did not receive parenterally administered Shuxuetong. Using propensity score, confounding factors were balanced between the two groups, three logistic regression methods were used to compare the groups following treatment for cerebral infarction. The three methods of comparison indicated that the use of Shuxuetong significantly increased cure rates compared to the control group. Therefore, based on existing data, for the treatment of cerebral infarction, the outcomes are more effective when combination therapy including Shuxuetong is used.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
